Myelo proliferative disorder (myeloid leukemia) vis-a-vis triyak raktapitta and its ayurvedic management – a clinico –theoretical review

2^nd World Congress on Cancer Science & Therapy

September 10-12, 2012 Hilton San Antonio Airport, USA

Nishant Shukla

AcceptedAbstracts: JCST

Abstract :

Myeloid leukemia (ML) is very commonly myelo proliferative disorder. The important pathophysiological change observed is the increased cellularity esp. of myeloid series. Thus it is resulting in the increase of the viscosity of blood i.e. lohitabhisyanda. This is the characteristic change observed in raktapitta. Thus it is kept at equality. Triyak raktapitta is advanced phase of the raktapitta where the blood oozes out even from the romakupa. This is tridoshaja condition and bears poor prognosis, because of non-effectiveness of therapeutic purification processes or limited availability of tridosha shamak drugs. It is observed that on the basis of the clinical experience that the chronic myeloid leukemia (CML) is managed effectively with providing good symptom relief and improving general wellbeing. The average life span of the patient is believed to be five to ten years, but it is observed that the life span of the patients managed with ayurvedic live even more than fifteen years. Tools for evaluation for the life expectancy are yet not very much perfect, so calming the improvement of life expectancy is not justified, but it is certain that the wellbeing of the patients improves with symptom relief.

Biography :

Dr. Nishant Shukla has completed his M.D. (Ayu) at the age of 25 years from Gujarat Ayurved University and postdoctoral studies is from Gujarat Ayurved University School of Kayachikitsa (Ayurvedic Medicine). He is the Lecturer of SGAM, Gujarat Ayurved University a premier Ayurvedic teaching organization. He has presented more than 25 papers in reputed conferences.